

## Percent of Long-Stay Residents Who Received an Antipsychotic Medication

### Quality Measure Description

This MDS 3.0 quality measure reports the percentage of long-stay residents who are receiving antipsychotic medications in the target period during the 7-day period preceding the MDS 3.0 target assessment date. This measure is used in the Five-Star Quality Rating System. This measure is reported on CASPER Reports and on Nursing Home Compare.

### Rationale for the Residents Who Received an Antipsychotic Medication

#### Quality Measure

Antipsychotic drugs are an important treatment for patients with certain mental health conditions. However, the FDA has warned that antipsychotic medications are associated with an increased risk of sudden death when used in elderly patients with dementia and the medications have side effects. Therefore, these medications must be used appropriately. Interventions that do not involve medications should be used first, if possible, and the continued use of antipsychotics should be carefully monitored or safer alternatives used. Residents taking antipsychotics should have drug reviews to eliminate negative outcomes related to drug-to-drug interactions. Interventions that do not require medications, such as higher staffing ratios, many and varied activities, and consistent assignment, have been shown to be successful in many cases.

#### NOTE:

A **black box warning** is the strictest warning put in the labeling of prescription drugs or drug products by the Food and Drug Administration (FDA) when there is reasonable evidence of an association of a serious hazard with the drug. Residents who are taking an antipsychotic with a black box warning *must have a signed consent on file* that includes the actual wording of the Black Box Warning.

### Quality Measure Specifications (N031.02)

#### Numerator

A resident will trigger this measure on the MDS 3.0 Facility Level Quality Measure Report if the most recent MDS 3.0 (Target Assessment) indicates that antipsychotic medications were received (N0410A = [1, 2, 3, 4, 5, 6, 7]).

#### Denominator

All long-stay residents with a selected target assessment, except those with exclusions.

#### Exclusions

1. The resident did not qualify for the numerator **and** the following is true: (N0410A = [-]).
2. **Any** of the following related conditions are present on the target assessment (unless otherwise indicated):
  - Schizophrenia (I6000 = [1]).
  - Tourette's syndrome (I5350 = [1]).
  - Tourette's Syndrome (I5350 = [1]) on the prior assessment if this item is not active on the target assessment **and** if a prior assessment is available.
  - Huntington's disease (I5250 = [1]).

***Covariates***

There are no covariates for this quality measure.

**MDS Elements Related to the Residents Who Received an Antipsychotic Medication Quality Measure**

<b>Active Diagnoses in the last 7 days - Check all that apply</b>	
Diagnoses listed in parentheses are provided as examples and should not be considered as all-inclusive lists	
<b>Neurological - Continued</b>	
<input type="checkbox"/>	I5250. Huntington's Disease
<input type="checkbox"/>	I5350. Tourette's Syndrome
<b>Psychiatric/Mood Disorder</b>	
<input type="checkbox"/>	I6000. Schizophrenia (e.g., schizoaffective and schizophreniform disorders)
<b>N0410. Medications Received</b>	
Indicate the number of DAYS the resident received the following medications during the last 7 days or since admission/entry or reentry if less than 7 days. Enter "0" if medication was not received by the resident during the last 7 days	
Enter Days <input type="text"/>	A. Antipsychotic

**Source:** MDS 3.0 Quality Measures User's Manual V 12.1